The story of the erectile dysfunction drug presents a complex picture for shareholders. While the initial introduction generated significant gains, the lapse of its intellectual property protection opened the door to cheaper competitors, dramatically diminishing market share. This poses a unique challenge for pharmaceutical companies banking on com

The history of Viagra, and its parent company copyright, presents a challenging case study for investors. At first a blockbuster drug, generating billions in sales , its patent expiration created a wave of lower-priced alternatives , significantly impacting its position . While specific businesses may attempt to capitalize on related treatments , t